“Nicotine withdrawal-related disruption of cognitive control may contribute to the reinforcement of tobacco use.
Identification of gene variants that predict this withdrawal phenotype may lead to tailored pharmacotherapy for smoking cessation.
Variation on the cannabinoid receptor 1 gene (CNR1) has been related to nicotine dependence, and CNR1 antagonists may increase attention and memory functioning.
The current findings suggest potential efficacy of cannabinoid RECEPTOR antagonism as a pharmacotherapy approach for smoking cessation among individuals who exhibit greater nicotine withdrawal-related cognitive disruption.”